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Aims Elevated homocysteinaemia is associated not only with an increased risk for cardiovascular disease but also for
increased morbidity and mortality in patients with established coronary artery or cerebrovascular disease.
Whether elevated homocysteine further increases the morbidity and mortality in patients undergoing cardiac
surgery on cardiopulmonary bypass (CPB) (a prothrombotic state itself) remains less known.
Methods
and results
Accordingly, we conducted a prospective observational study with pre-operative measurement of plasma homocys-
teine levels in 531 consecutive patients undergoing cardiac operations on CPB. The association of pre-operative
plasma homocysteine levels with post-operative morbidity and hospital mortality was evaluated. Elevated homocys-
teine levels (.15 mmol/L) were observed in 209 patients (39.4%), and homocysteinaemia was associated with a
higher mortality and perioperative morbidity (major morbidity, low cardiac output, acute renal failure, mesenteric
infarction, and thrombo-embolic events). Even after accounting for the differences in baseline clinical features,
EuroSCORE, and CPB time, pre-operative homocysteine levels remained independently associated with hospital
mortality [odds ratio (OR) 1.06, 95% conﬁdence interval (CI) 1.03–1.11], major morbidity (OR 1.04, 95% CI
1.01–1.07), low cardiac output (OR 1.04, 95% CI 1.02–1.08), mesenteric infarction (OR 1.06, 95% CI 1.01–1.11),
and thrombo-embolic events (OR 1.09, 95% CI 1.04–1.13). This association of homocysteine with increased risk
of morbidity and mortality was observed particularly in CABG patients.
Conclusion Elevated pre-operative homocysteine level is independently associated with increased morbidity and mortality,
particularly in patients undergoing CABG. Speciﬁc post-operative antithrombotic strategies may be advisable in
hyperhomocysteinaemic patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Homocysteine † Risk factors † Cardiac surgery † Outcomes
Introduction
Prior investigations have shown that hyperhomocysteinaemia
(HHC) is associated with an increased risk for cardiovascular
disease, including coronary artery disease, peripheral arterial
disease, stroke, and venous thrombosis.
1–5 Similarly, elevated
homocysteine levels have been demonstrated to be associated
with increased risk of morbidity and mortality in patients with
established coronary artery or cerebrovascular disease.
6–8
Evidence exists supporting signiﬁcant impact of homocysteine on
endothelial resistance to thrombosis as well as on vasodilatory
and antithrombotic effects of nitric oxide, potentially accounting
for some of the increased risks of these recurrent events in
patients with cardiovascular disease.
9–11
Patients undergoing cardiac surgery are at signiﬁcant risk for
serious adverse arterial and venous thrombotic events, including
myocardial infarction, unstable angina, mesenteric ischaemia,
stroke, pulmonary embolism, and deep vein thrombosis, resulting
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12–15 However, the
prevalence and/or the relationship of pre-operative homocysteine
with perioperative cardiovascular events have not been previously
explored adequately in this high-risk cohort. Accordingly, the
major goal of the current study was to ascertain the prevalence
of pre-operative HHC as well as evaluate its relationship with peri-
operative adverse events in patients undergoing cardiac surgery at
our institution. We hypothesized that many patients undergoing
cardiac surgery are likely to have elevated homocysteine levels
because of signiﬁcant epidemiological evidence linking homocys-
teine with cardiovascular disease.
1–5 Additionally, we theorized
that the high levels of plasma homocysteine may be potentially
associated with an increased thrombo-embolic risk in these
patients undergoing cardiac operations, and therefore may rep-
resent an independent risk factor for perioperative morbidity
and mortality.
Methods
Patient population and study design
Patients scheduled for cardiac operations at our institution (IRCCS
Policlinico S. Donato, Milan, Italy) have a plasma homocysteine level
measurement as a part of pre-operative assessment since the beginning
of the year 2007. For the purpose of this study, we included all adult
patients  18 years of age undergoing cardiac surgery requiring cardi-
opulmonary bypass (CPB) who had pre-operative homocysteine
measured. Patients were excluded if they had an off-pump surgery
or did not have a homocysteine measurement. All the patients gave
written informed consent to the scientiﬁc treatment of their clinical
data. Surgical and medical treatments were at the discretion of surgical
team in accordance with evidence-based guidelines, with no speciﬁc
treatment mandated or new intervention applied as a part of this
study. This observational study was approved by the local ethical com-
mittee in May 2007. As a result, only patients who underwent cardiac
surgery after 1 June 2007 were considered for this study.
Data collection
Data on patient demographic, past medical history, comorbid con-
ditions, details of surgical procedural information, perioperative labora-
tory values, management, and treatments, and post-operative
outcomes including length of stay and 30-day mortality are routinely
collected for all patients undergoing cardiac surgery at our institution.
For the purpose of this analysis, we linked this routinely collected
information from the institutional database to the homocysteine
laboratory data. The data elements are routinely ﬁlled out at three
different sites: ward (for pre- and late post-operative data); operating
room (for intra-operative data); and in the Intensive Care Unit
(ICU). The operative risk was determined according to the logistic
EuroSCORE; all the risk conditions were deﬁned according to the
EuroSCORE deﬁnitions.
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Anaesthesia, surgery, and cardiopulmonary
bypass
Pre-medication included atropine sulphate (0.5 mg), prometazine
(50 mg), and fentanyl (50–100 mg according to the patient’s weight)
intra-muscularly administered 1 h before the induction of anaesthesia.
Anaesthesia was induced with an intra-venous infusion of remifentanil
(starting dose 0.5 mgk g
21 min
21) and a midazolam bolus of 0.2 mg/kg.
Cisatracurium besylate (0.2 mg/kg) was subsequently administered to
allow tracheal intubation. Subsequently, anaesthesia was maintained
with a continuous infusion of remifentanil (dose ranging from 0.05 to
1 mgk g
21 min
21, titrated on the basis of the haemodynamic response)
and midazolam (0.1 mg kg
21 h
21) or propofol (3 mg kg
21 h
21).
Cardiopulmonary bypass was conducted using either closed or open
circuits, standard or phosphorylcholine-coated hollow-ﬁbre oxy-
genators, and roller or centrifugal pumps according to availability.
Regardless of the circuit used, the priming volume was always mini-
mized to 800–1000 mL. Lowest core body temperature during CPB
varied from 27 to 378C as requested by the surgeon. Antegrade inter-
mittent cold crystalloid or cold blood cardioplegia was used according
to the surgeon’s preference. The pump ﬂow was targeted between 2.0
and 2.8 L min
21 m
22, and the target mean arterial pressure was settled
at 60 mmHg. Anticoagulation was established with an initial dose of
300 IU per kilogram of body weight of porcine intestinal heparin
injected into a central venous line 10 min before the initiation of
CPB and a target-activated clotting time of 480 s; patients receiving
closed and biocompatible circuits received a reduced dose of
heparin with a target-activated clotting time settled at 300 s. At the
end of CPB, heparin was reversed by protamine chloride at a 1:1
ratio of the loading dose, regardless of the total heparin dosage.
Homocysteine measurement
To determine the pre-operative serum homocysteine value, venous
blood samples were taken between 7.30 and 9.00 a.m. (after overnight
fast), usually the day before the operation. Blood samples were col-
lected in tubes containing EDTA, immediately placed on ice, and
plasma was separated within 1 h. Plasma was stored at –208C until
analysis. Total plasma homocysteine levels were determined using an
immunoﬂuorescence method (AxSYM, Abbott) already validated for
this type of analysis,
17 and applied in a previous large randomized con-
trolled trial.
18 The method included a standard 6-points calibration; for
patients with levels of homocysteine exceeding 50 mmol/L, an auto-
mated dilution protocol was applied. The inter-day coefﬁcient of vari-
ation of the analytic method was 4.36, 5.64, and 6.55%, respectively, for
control samples containing a high, medium, and low homocysteine
concentration. Hyperhomocysteinaemia was deﬁned as a plasma
level of homocysteine exceeding 15 mmol/L.
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Sample size estimation
The primary endpoint was to investigate the possible association
between plasma homocysteine levels and complications and mortality
following cardiac operations. The sample size was determined by a
power analysis targeted on thrombo-embolic complications and
based on the available data and some assumptions outlined as follows:
(i) The post-operative thrombo-embolic complication rate (myocar-
dial infarction, stroke, mesenteric infarction, pulmonary and per-
ipheral embolism) was ascertained using the Institutional
Database for patients operated between 2000 and 2006 (n ¼
8,126 patients). The total thrombo-embolic complication rate
was 4.8% (myocardial infarction 3.0%, stroke 1.4%, mesenteric
infarction 0.3%, pulmonary and peripheral embolism 0.1%).
(ii) The experimental hypothesis was that patients with HHC would
have a higher rate of post-operative thrombo-embolic events than
patients without HHC. The rate of thrombo-embolic events in
patients with HHC was assumed to be twice that in those
without HHC.
(iii) The prevalence of HHC in the cardiac surgical population is
unknown. However, it is reasonable to assume it to be higher
in patients with cardiovascular disease than the 11% prevalence
of HHC described in the European population.
18 Considering
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from the ﬁrst three months of 2007, we assumed a prevalence
of HHC of 30% in our patient population.
(iv) Based on the overall event rate of 4.8% in the 8126 patients
undergoing cardiac surgery between 2000 and 2006 and on
these assumptions for the prevalence of HHC (30%) as well as
twice the expected event rate in HHC patients compared with
those without it, we estimated an event rate of 3.7% for
non-HHC patients and 7.4% for HHC patients.
(v) Therefore, the sample size was settled at 520 patients, with a pre-
dicted distribution of 364 non-HHC and 156 HHC subjects, with
predicted thrombo-embolic event numbers of, respectively, 13
(3.7%) and 12 (7.4%), relative risk 2.2, 95% conﬁdence interval
1.003–5.05, and P , 0.05.
Statistical analysis
Data are expressed as median with interquartile range for continuous
variables and as number and percentage for binary categorical vari-
ables. Homocysteine values were treated as a continuous variable in
all the statistical tests. For display purpose in the tables, homocysteine
was grouped into quintiles to show the distribution and values of peri-
operative and outcome variables.
The following perioperative variables were tested for univariate
association with homocysteine levels: demographics and past medical
history (hypertension, diabetes on medication, chronic obstructive pul-
monary disease, peripheral vascular disease, heart failure, recent myo-
cardial infarction, unstable angina, congestive heart failure, left
ventricular ejection fraction, pre-operative use of intra-aortic balloon
pump, prior vascular surgery, prior cardiac surgery, prior cerebrovas-
cular accident, chronic dialysis, serum creatinine value, creatinine clear-
ance, haematocrit). Mortality risk was assessed with the logistic
EuroSCORE. Operative variables considered were: type of operation,
CPB duration, aortic cross-clamping duration, lowest haematocrit on
CPB, and lowest temperature on CPB.
The univariate association of homocysteine levels with the following
outcome variables was also assessed: time on ventilator, ICU stay, hos-
pital stay; in-hospital mortality; acute renal failure, peak serum creati-
nine value, atrial ﬁbrillation (new onset), ventricular arrhythmias,
pneumonia, sepsis, mediastinitis, stroke, re-operation for bleeding,
severe bleeding, need for allogeneic blood transfusions, low cardiac
output syndrome, myocardial infarction, lung dysfunction, mesenteric
infarction, any thrombo-embolic event (myocardial infarction, stroke,
mesenteric infarction, pulmonary or systemic embolism), and major
morbidity (any of the following: need for re-operation, sternal
wound infection, permanent stroke, renal failure, mechanical venti-
lation for .48 h).
Differences in homocysteine values were tested using a Student’s
t-test for independent samples (binary variables) or an analysis of var-
iance for continuous variables. The association between pre-operative
homocysteine levels and outcome variables was tested with a multi-
variable logistic regression or linear regression analysis (as appropri-
ate), generating the odds ratio (for 1 U change in homocysteine
level) with 95% conﬁdence interval.
To avoid overﬁtting of the models, a limited number of independent
variables were admitted after accounting for different comorbidities,
the absence of multicollinearity, and their clinical importance as
deﬁned by previous studies. These variables included EuroSCORE
and CPB duration for all outcome variables and pre-operative serum
creatinine for acute renal failure. The risk for Type I error due to mul-
tiple testing was addressed using a Bonferroni correction for the
P-values required to reject the null hypothesis. Multicollinearity
within multivariable models was addressed with a multicollinearity
diagnostics and tolerance statistics.
Sensitivity analysis was also performed to evaluate the association of
pre-operative homocysteine with outcomes in patients undergoing
CABG and/or valves and in patients with isolated valve surgery.
The predictive value of pre-operative homocysteine in determining
the thrombo-embolic events and the hospital mortality rate was
tested with a receiver operating characteristics (ROC) analysis, with
assessment of the area under the curve (AUC) and standard error of
the AUC. Cut-off values were searched and tested for sensitivity and
speciﬁcity (with 95% conﬁdence interval). The cut-off point assessment
was based on the pre-requisite of a sensitivity of at least 70%, based on
the coordinates of the ROC curve. The cut-off values were settled at
the point where the sum of sensitivity and speciﬁcity was the highest,
according to Youden’s index: (sensitivity þ speciﬁcity)21.
The ROC estimates were validated with bootstrapping techniques,
which involved drawing a random sample of 531 cases (with replace-
ment) from the original sample of 531 cases. A P-value ,0.05 was con-
sidered signiﬁcant for all the statistical tests. All the statistical tests
were two-sided. Statistical calculations were performed using a com-
puterized statistical program (SPSS 13.0, Chicago, IL, USA).
Results
Study population and patients’
demographic and surgical data
Between June 2007 and January 2008, 820 patients underwent
cardiac surgical procedures at our institution. Of these, 205
patients who had paediatric cardiac surgery, 35 patients who
received an off-pump operation, and 49 cases with no pre-
operative value of homocysteine available due to technical labora-
tory problems or to the emergent condition of the operation were
excluded from this analysis. The remaining 531 patients formed the
basis of this study, fulﬁlling the estimated sample size.
The 49 cases excluded due to unavailability of the pre-operative
homocysteine value had signiﬁcantly higher rate of emergent oper-
ations (20 vs. 0.2%, P , 0.001), EuroSCORE (7.5+2 vs. 6.4+7.6,
P ¼ 0.017), heart failure (20 vs. 0.2%, P , 0.001), and intra-aortic
balloon pump use (6 vs. 0.2%, P ¼ 0.002) and lower left ventricular
ejection fraction (48+13 vs. 52+11, P ¼ 0.022). The other pre-
and intra-operative factors were not signiﬁcantly different.
Demographics, pre-operative and operative data of our patient
population are reported in Tables 1 and 2 for the overall popu-
lation and for quintiles of distribution of the homocysteine level.
The mean pre-operative homocysteine level in our patient popu-
lation was 15.4+8.3 mmol/L and the median value was
13.7 mmol/L (IQR 10.5–17.4 mmol/L, range 1.7–92 mmol/L). In
the subgroup of patients with coronary artery disease, the baseline
values were 15.7+8.6 mmol/L and the median value was
13.9 mmol/L (IQR 10.6–17.5 mmol/L, range 1.7–92 mmol/L).
A total of 209 patients (39.4%) had a pre-operative plasma
homocysteine level .15 mmol/L, fulﬁlling the deﬁnition for
HHC. There was a signiﬁcant positive association between homo-
cysteine level and age, gender male, serum creatinine value, Euro-
SCORE, and CPB duration; and an inverse association with left
ventricular ejection fraction and creatinine clearance.
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Table 1 Demographics and clinical features in the overall population and homocysteine quintiles
Factor All patients Homocysteine subgroups (quintiles)–range (mmol/L) P-value
Median (IQR) or n(%) I (1.7–9.8) II (9.9–12.5) III (12.6–14.8) IV (14.9–19.1) V (19.2–92.3)
Demographics
Age (years) 68 (59–74) 65 (56–70) 66 (55–71) 69 (59–70) 70 (59–76) 71 (61–77) 0.001
Gender, male 375 (70.6) 59 (56) 74 (69) 79 (74) 79 (74) 84 (78) 0.021
Height (cms) 168 (160–174) 165 (160–171) 168 (162–174) 168 (160–173) 168 (162–174) 170 (161–175) 0.179
Weight (kg) 73 (65–80) 74 (53–83) 74 (63–80) 72 (66–79) 75 (65–83) 72 (65–80) 0.317
Past medical history
Hypertension 220 (41.4) 41 (39) 41 (38) 46 (43) 46 (44) 46 (43) 0.182
Diabetes mellitus 57 (10.7) 15 (14) 6 (6) 14 (13) 7 (7) 15 (14) 0.939
COPD 21 (4.0) 2 (2) 5 (5) 4 (4) 3 (3) 7 (6) 0.146
PVD 48 (9.0) 8 (8) 10 (9) 9 (9) 11 (10) 10 (9) 0.128
Heart failure 1 (0.2) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0.895
Prior cardiac surgery 22 (4.1) 2 (2) 5 (4) 4 (4) 7 (7) 4 (4) 0.983
Prior vascular surgery 21 (4.0) 1 (1) 1 (1) 7 (7) 3 (3) 9 (8) 0.092
Prior CVA 15 (2.8) 1 (1) 4 (4) 4 (4) 2 (2) 4 (4) 0.408
Chronic dialysis 9 (1.7) 1 (1) 0 (0) 1 (1) 4 (4) 3 (3) 0.216
Recent MI (,30 days) 45 (8.5) 13 (12) 3 (3) 8 (8) 9 (9) 12 (11) 0.387
Unstable angina 30 (5.6) 6 (6) 10 (9) 5 (5) 3 (3) 6 (6) 0.176
Pre-operative CHF 16 (3.0) 4 (4) 1 (1) 1 (1) 4 (4) 6 (6) 0.301
Pre-operative IABP 1 (0.2) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0.895
Left ventricular EF (%) 54 (45–60) 55 (50–60) 55 (48–60) 53 (45–60) 53 (41–60) 50 (38–57) 0.001
Serum creatinine (mg/dL) 1 (0.8–1.2) 0.8 (0.7–1.0) 0.8 (0.8–1.0) 1.0 (0.8–1.1) 1.0 (0.8–1.2) 1.2 (1.0–1.6) 0.001
Creatinine clearance (mL/min) 75.5 (54.7–95.5) 85 (71–105) 88 (67–114) 72 (58–91) 72 (50–93) 57 (34–86) 0.001
Haematocrit (%) 39 (36–42) 39 (36–42) 40 (37–42) 39 (35–42) 40 (37–42) 38 (34–42) 0.110
Homocysteine level (mmol/L) 13.7 (10.5–17.4) 8.3 (7–9) 11.2 (11–12) 13.8 (13–14) 16.2 (16–17) 24.2 (21–28) 0.001
Hyperhomocysteinaemia 209 (39.4) 0 (0) 0 (0) 0 (0) 100 (96) 109 (100) 0.001
EuroSCORE 4 (2.1–7) 3.1 (2–5) 3.5 (2–7) 4 (2–7) 5 (3–7) 6 (3–10) 0.001
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; EF, ejection fraction; IABP, intra-aortic balloon pump; IQR, interquartile range; MI, myocardial infarction; PVD, peripheral vascular
disease.
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8Association of homocysteinaemia with
perioperative events
Pre-operative homocysteine level (Table 3) was signiﬁcantly associ-
ated with the time on ventilator, the ICU stay, and the peak post-
operative serum creatinine value. It was signiﬁcantly higher in
patients who developed acute renal failure, low cardiac output,
and major morbidity. A trend towards higher homocysteine
values was observed in patients suffering from thrombo-embolic
events and hospital mortality. Results of multivariable linear or
logistic regression models having outcome variables as dependent
variables and pre-operative homocysteine level as independent
variable are shown in Table 4. Only events occurring in at least
ﬁve patients (1%) have been considered. The tolerance values
for each independent variable were always .0.8, thus excluding
multicollinearity risk. After the Bonferroni correction, the P-value
to reject the null hypothesis in the setting of 18 different outcomes
comparison was determined to be 0.0028.
Even after accounting for differences in baseline EuroSCORE
and time of CPB (and in case of acute renal failure, also pre-
operative serum creatinine), homocysteine level was an indepen-
dent risk factor for prolonged mechanical ventilation time,
in-hospital need for transfusion(s), low cardiac output syndrome,
mesenteric infarction, any thrombo-embolic events, and mortality.
Furthermore, despite the conservative P-value after the Bonferroni
correction, the association between homocysteine and various
outcomes persisted (signiﬁcantly or showed a non-signiﬁcant
trend). Particularly, any thrombo-embolic event and mortality
still remained highly statistically signiﬁcant despite this conservative
P-value accounting for multiple comparisons.
Although, our estimate of sample size was not based exclusively
on CABG patients, sensitivity analysis demonstrated that the risk of
any thrombo-embolic event (adjusted OR 1.09, 95% CI 1.02–1.16,
P ¼ 0.007) and in-hospital mortality (adjusted OR 1.09, 95% CI
1.02–1.17, P ¼ 0.01) were signiﬁcantly associated with homo-
cysteine level in the subgroup of patients undergoing CABG with
or without valve surgery (Table 4). Trends were also observed
for the association between homocysteine and outcomes in the
subgroup of patients with CABG after the Bonferroni correction.
Whereas similar higher trends for any thrombo-embolism
(adjusted OR 1.05, 95% CI 0.96–1.12, P ¼ 0.31) and in-hospital
mortality (adjusted OR 1.02, 95% CI 0.93–1.12, P ¼ 0.67) were
noted among patients undergoing valvular surgery, these differ-
ences were not statistically signiﬁcant. Figure 1 depicts the unad-
justed and adjusted mortality rates (derived using multivariable
logistic regression analysis) as a function of the pre-operative
homocysteine value in patients undergoing any cardiac surgery
and in those undergoing CABG.
Finally, we explored the value of pre-operative homocysteine
levels in predicting the mortality and thrombo-embolic compli-
cations and in-hospital mortality risk applying an ROC analysis.
The results for the crude patient population and for the internal
validation obtained with a bootstrap technique are reported in
Table 5. Pre-operative homocysteine levels have an acceptable pre-
dictive ability for thrombo-embolic events (AUC 0.71), but lower
for in-hospital mortality (AUC 0.68). Similar values were detected
in the bootstrap series. Values of homocysteine around 15 mmol/L
were associated with a sensitivity and speciﬁcity of 70 and 64%
(thrombo-embolic events) and 69 and 61% (in-hospital mortality),
respectively. However, the low level of speciﬁcity and the large
95% CI preclude robust conﬁrmation of these values as being clini-
cally relevant.
Discussion
Our study ﬁndings
Our data suggest that the prevalence of pre-operative HHC is high,
with two of every ﬁve patients undergoing cardiac surgery having
elevated homocysteine values .15 mmol/L. Importantly, HHC
was independently associated with increased risk of perioperative
morbidity and mortality. This increased risk of adverse events
was only partially explained by older age and greater comorbid
conditions such as lower left ventricular ejection fraction and
lower creatinine clearance in this cohort (accounting for their
higher EuroSCORE) as even after adjustment for these baseline
confounders, HHC remained an independent correlate of higher
need for transfusion, acute renal failure, low cardiac output syn-
drome, any thrombo-embolic event, but more importantly,
.............................................................................................
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Table 2 Cardiac surgical data in the overall population and homocysteine quintiles
Factor All patients Homocysteine subgroups (quintiles)—range (mmol/L) P-value
Median (IQR) or n (%) I (1.7–9.8) II (9.9–12.5) III (12.6–14.8) IV (14.9–19.1) V (19.2–92.3)
Isolated coronary surgery 262 (49.3) 49 (46) 51 (48) 61 (57) 44 (41) 57 (52) 0.637
Isolated valve surgery 156 (29.4) 43 (41) 29 (27) 24 (22) 32 (30) 28 (26) 0.317
Combined procedure 113 (21.3) 16 (15) 26 (24) 21 (19) 30 (28) 20 (18) 0.102
CPB duration (min) 68 (54–95) 62 (52–84) 68 (52–92) 65 (51–101) 75 (57–95) 70 (55–96) 0.048
Closed, biocompatible circuits 145 (27) 28 (27) 33 (31) 28 (27) 28 (27) 28 (27) 0.965
Aortic cross-clamp time 45 (35–66) 42 (35–62) 47 (36–64) 42 (34–62) 49 (37–69) 46 (33–45) 0.424
Nadir haematocrit on CPB (%) 27 (24–29) 27 (24–29) 28 (25–30) 27 (24–29) 28 (24–31) 26 (24–29) 0.966
Nadir temperature on CPB (8C) 32 (31.7–33) 32 (32–33) 32 (32–33) 32 (32–33) 32 (31–33) 32 (32–33) 0.747
CPB, cardiopulmonary bypass; IQR, interquartile range.
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Table 3 Clinical events in the overall population and homocysteine quintiles
Factor All patients Homocysteine subgroups (quintiles)—range (mmol/L) P-value
Median (IQR) or n(%) I (1.7–9.8) II (9.9–12.5) III (12.6–14.8) IV (14.9–19.1) V (19.2–92.3)
Length of stay
Time on ventilator (h) 12 (9–20) 11 (7–15) 11.5 (8–16) 12 (10–24) 13 (10–20) 16 (11–38) 0.004
ICU stay (days) 2 (1–4) 2 (1–3) 2 (1–3) 2 (1–4) 2 (1–3) 3 (1–6) 0.004
Hospital stay/days) 7 (1–11) 7 (1–10) 8 (1–12) 7 (1–10) 7 (1–10) 8 (1–12) 0.924
In-hospital events
Death 18 (3.4) 1 (1) 2 (2) 3 (3) 5 (5) 7 (6) 0.073
Mediastinitis 6 (1.1) 1 (1) 0 (0) 2 (2) 2 (2) 1 (1) 0.972
Peak serum creatinine (mg/dL) 1 (0.8–1.3) 0.8 (0.7–1.0) 0.9 (0.7–1.1) 1.0 (0.9–1.3) 1.1 (0.8–1.6) 1.2 (0.9–1.8) 0.001
Acute renal failure 23 (3.8) 1 (1) 3 (3) 4 (4) 3 (3) 12 (11) 0.016
Atrial ﬁbrillation 27 (5.1) 6 (6) 6 (6) 4 (4) 3 (3) 8 (7) 0.870
Ventricular arrhythmias 3 (0.6) 1 (1) 0 (0) 2 (2) 2 (2) 1 (1) 0.836
Pneumonia 4 (0.8) 1 (1) 0 (0) 1 (1) 1 (1) 1 (1) 0.287
Sepsis 9 (1.7) 0 (0) 0 (0) 3 (3) 3 (3) 3 (3) 0.522
Stroke 2 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 0.381
Re-operation for bleeding 9 (1.7) 2 (2) 2 (2) 1 (1) 1 (1) 3 (3) 0.652
Bleeding .1000 mL 29 (5.5) 6 (6) 4 (4) 5 (5) 4 (4) 10 (9) 0.128
Allogeneic transfusions 105 (19.8) 15 (14) 13 (12) 20 (19) 19 (18) 38 (35) 0.001
Low output syndrome 70 (13.2) 7 (7) 9 (8) 17 (16) 10 (9) 27 (25) 0.001
Myocardial infarction 7 (1.3) 1 (1) 1 (1) 2 (2) 2 (2) 1 (1) 0.893
Lung dysfunction 8 (1.6) 1 (1) 0 (0) 2 (2) 2 (2) 2 (2) 0.675
Mesenteric infarction 5 (0.9) 0 (0) 1 (1) 0 (0) 1 (1) 3 (3) 0.087
Any thrombo-embolic event 16 (3.0) 1 (1) 2 (2) 2 (2) 3 (3) 8 (8) 0.052
Major morbidity
a
Overall patients 34 (6.4) 3 (3) 4 (4) 7 (7) 4 (4) 16 (15) 0.007
CABG patients (n¼332) 24 (7.1) 2 (3.4) 2 (2.9) 5 (6.7) 3 (5.2) 12 (16) 0.012
Non-CABG patients (n¼199) 10 (5.2) 1 (2.1) 2 (5.4) 2 (6.5) 1 (2.2) 4 (12.1) 0.438
CABG, coronary artery bypass graft; ICU, intensive care unit; IQR, interquartile range.
aDeﬁned as the presence of any one of the following: need for re-operation, sternal wound infection, permanent stroke, renal failure, and/or prolonged ventilation (deﬁned as .48 h).
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1
0
0
0in-hospital mortality. The association of elevated homocysteine
level with mortality was observed predominantly among patients
undergoing CABG, but not in patients undergoing isolated valve
surgery.
Comparison with previous studies
The association between homocystinuria, a genetic disorder with
extremely high plasma homocysteine levels (in excess of
100 mmol/L), and premature atherosclerosis, increased risk of
thrombo-embolism and premature death has been known for
more than last ﬁve decades.
20,21 This knowledge subsequently
lead to series of epidemiological investigations that have consist-
ently shown that even moderate elevation of homocysteine is
associated with increased risk of coronary artery disease, periph-
eral arterial disease, stroke, and venous thrombo-embolic
disease.
1–5Additionally, in patients with established cardiovascular
disease, elevated homocysteine levels are related to higher mor-
bidity and mortality risk.
6–8
................................................................. ....................................................................
...............................................................................................................................................................................
Table 4 Multivariable analyses (linear or logistic regression) for outcome variables association with pre-operative
homocysteinaemia
Outcome variable Multivariable analysis
a (overall patients) Multivariable analysis
a (CABG patients)
b (95% CI) OR (95% CI) P-value b (95% CI) OR (95% CI) P-value
Mechanical ventilation 0.796 (0.178–1.415) – 0.012
b 0.956 (0.154–1.759) – 0.020
b
ICU stay 0.053 (0.003–0.109) – 0.063 0.057 (20.022–0.137) – 0.159
Hospital mortality 0.063 (0.03–0.104) 1.06 (1.03–1.11) 0.001 0.091 (0.02–0.157) 1.09 (1.02–1.17) 0.010
b
Allogeneic transfusions 0.045 (0.02–0.068) 1.05 (1.02–1.07) 0.001 0.047 (0.01–0.086) 1.05 (1.01–1.09) 0.022
b
Low cardiac output 0.045 (0.02–0.077) 1.04 (1.02–1.08) 0.002 0.058 (0.02–0.104) 1.06 (1.02–1.11) 0.010
b
Acute renal failure
c 0.038 (0.01–0.068) 1.04 (1.01–1.07) 0.031
b 0.084 (0.01–0.157) 1.09 (1.01–1.17) 0.031
b
Mesenteric infarction 0.056 (0.01–0.104) 1.06 (1.01–1.11) 0.014
b 0.104 (0.03–0.174) 1.11 (1.03–1.19) 0.006
b
Thrombo-embolic events 0.082 (0.039–0.122) 1.09 (1.04–1.13) 0.001 0.085 (0.02–0.148) 1.09 (1.02–1.16) 0.007
b
Major morbidity 0.041 (0.01–0.068) 1.04 (1.01–1.07) 0.008
b 0.067 (0.02–0.113) 1.07 (1.02–1.12) 0.008
b
aAdjusted for EuroSCORE and cardiopulmonary bypass duration.
bNot signiﬁcant after Bonferroni correction.
cAdjusted for EuroSCORE, cardiopulmonary bypass duration, and pre-operative serum creatinine value.
Figure 1 The relationship between pre-operative plasma homocysteine values and in-hospital mortality (undajusted and adjusted-derived
using multivariable logistic regression analysis) for patients undergoing any cardiac surgery (dashed lines) and for those undergoing coronary
artery bypass graft surgery (continuous lines).
Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery 1001Storti et al.
22 studied the changes in homocysteine levels in a
population of patient who underwent coronary revascularization.
They detected a mean pre-operative value (17.3 mmol/L) higher
than the one found in the present study for coronary patients.
The homocysteine levels signiﬁcantly decreased after the oper-
ation. No outcome analyses were performed in this study, which
included a limited (48) number of patients.
Our data in the CABG population suggest heightened risk of
perioperative morbidity and mortality in patients with elevated
homocysteine undergoing surgical coronary revascularization.
However, the previously quoted studies suggested that in patients
with cardiovascular disease, elevated homocysteine levels confer
heightened risk of adverse events over intermediate or long-term
follow-up.
1–8 Our data complement these results, indicating that
this increased risk is observed even acutely (in perioperative
period) in CABG patients. This is not surprising if one were to con-
sider the prevailing hypothesis on the mechanisms underlying the
association of elevated homocysteine with adverse outcomes in
patients with cardiovascular disease. A high level of homocysteine
impairs endothelial function
9 and decreases the bioavailability of
nitric oxide from endothelial cells.
10 It also reduces the afﬁnity of
antithrombin (an anticoagulant) to bind to endothelial cells.
23
Finally, it appears that homocysteine may limit the coagulation
inhibitory effect normally exerted by the thrombomodulin-protein
C complex through a reduction in protein C activation rate.
24
These mechanisms decrease endothelial resistance to thrombosis,
reduce vasodilatory effects of nitric oxide, and promote thrombo-
sis. Similarly, cardiac operations with CPB itself lead to the hyper-
coaguable state by the generation of massive doses of thrombin
that consumes antithrombin,
25 by decreasing nitric oxide syn-
thesis,
25,26 and by reducing protein C and tissue factor pathway
inhibitor.
27 Therefore, it is easy to comprehend why elevated
homocysteine may further aggravate the hypercoaguable state
observed among patients undergoing CABG, thereby compound-
ing the thrombo-embolic risk in these patients.
That perhaps these mechanisms are operative is supported to
some extent by the fact that the great majority of perioperative
complications observed in patients with elevated homocysteine
undergoing cardiac surgery seem to be thrombo-embolic events
resulting from either macrovascular clots in mesenteric and cer-
ebral circulation (mesenteric infarction and a non-signiﬁcant
increase in stroke) or microvascular thrombosis in coronary and
renal microcirculation (low cardiac output and acute renal
failure). As a matter of fact, the highest odd of an adverse event
associated with elevated homocysteine level was with total
thrombo-embolic events (9% probability increase for each
1 mmol/L increment).
Clinical implications
Is there a role for routine measurement of homocysteine in the
management of patients undergoing cardiac surgery? Our data
suggest that perhaps homocysteine imparts additional prognostic
information for morbidity and mortality risk in cardiac surgery.
Whether expense of routine measurement of homocysteine can
be justiﬁed will depend on whether modiﬁcation (or reduction)
of this risk marker will improve outcomes in this cohort and the
extent to which it is improved. Supplementation of diet with
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M. Ranucci et al. 1002folic acid, vitamin B6, and vitamin B12 has been shown to decrease
homocysteine levels.
28 Despite this, treating patients who have
elevated homocysteine with these vitamins has failed to decrease
cardiovascular morbidity and mortality in two recently completed
large randomized controlled trials.
18,29 In view of these ﬁndings, a
similar dietary approach in patients with elevated homocysteine
levels scheduled for cardiac operations is not expected to decrease
their operative risks. However, this remains to be proven in future.
Alternatively, it is possible that early identiﬁcation of patients at
high-risk of perioperative thrombo-embolic events may allow
modiﬁcation of the surgical approach, i.e. the use of off-pump
surgery that may improve outcomes of these patients. Further-
more, a number of studies have demonstrated that after cardiac
operations the endothelial anticoagulant properties are exhausted
(low levels of antithrombin and protein C-S complex),
25,26,30 and
some investigations have suggested that pharmacological sup-
plementation with antithrombin may in fact be beneﬁcial in
improving outcomes of these individuals.
25,30 Since the risk of
thrombotic complications after cardiac surgery is increased by
the presence of elevated pre-operative homocysteine levels, the
present studies generate a hypothesis that patients with HHC
may perhaps beneﬁt from supplementation of such natural anticoa-
gulants. Additionally, strategies such as aggressive treatment with
antiplatelet or anticoagulant drugs in this high-risk subset for peri-
operative thrombotic events may also have the potential for redu-
cing the risk of these events in this cohort. However, these
hypotheses remain merely speculative at this time and need to
be tested and proved in future investigations.
Limitations
This observational study should be regarded as hypothesis gener-
ating and caution should be exerted while inferring causation. This
single tertiary centre study needs validation in future prospective
investigation involving large number of patients undergoing
cardiac surgery at large number of hospitals. The inﬂuence of elev-
ated homocysteine levels on intermediate and long-term outcomes
was not assessed. Finally, in patients undergoing emergent pro-
cedures, collecting information on homocysteine was not a pri-
ority. As such, there was a higher prevalence of emergent
procedures in the 49 patients with missing homocysteine data.
Thus, the prognostic signiﬁcance of homocysteine in patients
undergoing emergent CABG needs to be conﬁrmed in future
studies.
Conclusions
Elevated homocysteine levels are commonly observed in patients
undergoing cardiac surgery. This increase is independently associ-
ated with higher perioperative thrombo-embolic events and mor-
tality in these patients, particularly those undergoing CABG. Future
studies evaluating strategies and alternative surgical approaches
that would allow reduction in the high perioperative risk in patients
with elevated homocysteine are in order.
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